DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc.verified

DMAC

Price:

$5.65

Market Cap:

$304.44M

DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Min...[Read more]

Industry

Biotechnology

IPO Date

2012-08-03

Stock Exchange

NASDAQ

Ticker

DMAC

The Enterprise Value as of June 2026 (TTM) for DiaMedica Therapeutics Inc. (DMAC) is 299.78M

According to DiaMedica Therapeutics Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 299.78M. This represents a change of -1.69% compared to the average of 304.93M of the last 4 quarters.

DiaMedica Therapeutics Inc. (DMAC) Historical Enterprise Value (quarterly & annually)

How has DMAC Enterprise Value performed in the past?

The mean historical Enterprise Value of DiaMedica Therapeutics Inc. over the last ten years is 102.23M. The current 299.78M Enterprise Value has changed 29.22% with respect to the historical average. Over the past ten years (40 quarters), DMAC's Enterprise Value was at its highest in in the March 2026 quarter at 359.53M. The Enterprise Value was at its lowest in in the December 2016 quarter at 8.83M.

Quarterly (TTM)
Annual

Average

102.23M

Median

63.63M

Minimum

5.73M

Maximum

358.56M

DiaMedica Therapeutics Inc. (DMAC) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of DiaMedica Therapeutics Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 849.40%

Maximum Annual Enterprise Value = 358.56M

Minimum Annual Increase = -79.24%

Minimum Annual Enterprise Value = 5.73M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2025358.56M65.45%
2024216.71M145.30%
202388.34M135.45%
202237.52M-48.48%
202172.83M-51.99%
2020151.71M178.69%
201954.44M849.40%
20185.73M-79.24%
201727.61M210.87%
20168.88M20.52%

DiaMedica Therapeutics Inc. (DMAC) Average Enterprise Value

How has DMAC Enterprise Value performed in the past?

The current Enterprise Value of DiaMedica Therapeutics Inc. (DMAC) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

221.21M

5-year avg

154.79M

10-year avg

102.23M

DiaMedica Therapeutics Inc. (DMAC) Enterprise Value vs. Peers

How is DMAC’s Enterprise Value compared to its peers?

DiaMedica Therapeutics Inc.’s Enterprise Value is greater than Altimmune, Inc. (168.60M), greater than Galectin Therapeutics Inc. (297.44M), greater than enGene Holdings Inc. (79.79M), less than I-Mab (1.13B), less than Annexon, Inc. (413.52M), less than Alpha Tau Medical Ltd. (895.61M), greater than Korro Bio, Inc. (96.75M), less than Design Therapeutics, Inc. (675.12M), less than DBV Technologies S.A. (366.68M), greater than Genelux Corporation (104.57M),

CompanyEnterprise ValueMarket cap
168.60M$230.35M
297.44M$175.84M
79.79M$82.94M
1.13B$542.01M
413.52M$563.29M
895.61M$889.71M
96.75M$115.56M
675.12M$685.15M
366.68M$416.60M
104.57M$111.35M

Build a custom stock screener for DiaMedica Therapeutics Inc. (DMAC) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like DiaMedica Therapeutics Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

DiaMedica Therapeutics Inc. (DMAC) and other stocks custom spreadsheet templates

The easiest way to analyze a company like DiaMedica Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is DiaMedica Therapeutics Inc.'s Enterprise Value?

What is the highest Enterprise Value for DiaMedica Therapeutics Inc. (DMAC)?

What is the 3-year average Enterprise Value for DiaMedica Therapeutics Inc. (DMAC)?

What is the 5-year average Enterprise Value for DiaMedica Therapeutics Inc. (DMAC)?

How does the current Enterprise Value for DiaMedica Therapeutics Inc. (DMAC) compare to its historical average?